In the western Sweden series, patients whose GIST expressed FGL2 had longer RFS than patients whose GIST did not express FGL2 (hazard ratio [HR] =0.51; 95% CI: 0.31–0.84; log‐rank test p = 0.007), longer overall survival (HR =0.50; 95% CI: 0.30–0.82; p = 0.005), and longer GIST‐specific survival (HR = 0.30; 95% CI: 0.15–0.60; p < 0.001) in univariable survival analyses (Figure 2A‐C). This evidence concerns the gene FGL2 and gastrointestinal stromal tumor.